Alps Group Inc
Income Statement
| Line Item | FY2026 | FY2025 |
|---|---|---|
| Revenue | $4.9M | $3.4M |
| Cellular therapy | $883.0K | $586.4K |
| Medical testing, laboratory and aesthetics services | $3.1M | $2.6M |
| Consultation fee | $92.3K | $157.5K |
| Sales of medicine and healthcare products | $731.8K | $10.0K |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| Gross Margin | — | — |
| Operating Expenses | ||
| Research & Development | — | — |
| SG&A Expense | — | — |
| Operating Income | — | — |
| Operating Margin | — | — |
| Interest Expense | — | — |
| Pretax Income | — | — |
| Income Tax Expense | — | — |
| Net Income | — | — |
| Net Margin | — | — |
| EPS (Basic) | — | — |
| EPS (Diluted) | — | — |
| Shares Outstanding (Basic) | 166.4M | — |
| Shares Outstanding (Diluted) | 166.4M | — |
| Dividends Per Share | — | — |